IMM (IMM) News
Follow IMM (IMM) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 15 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Immutep Limited (IMM) Receives A$0.86M R&D Tax Rebate
Immutep received an A$856,669 cash rebate under Australia’s R&D tax incentive for FY2025 and plans to use it for efti and IMP761. The company says its expected cash reach extends into H1 CY2028.Material DetailsContext by
NEWS | Sep 30, 2026, 12:08 PM UTC
L
Immutep Receives ~A$0.86 Million R&D Tax Incentive
SYDNEY, AUSTRALIA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces th
NEWS | Sep 30, 2026, 12:08 PM UTC
M
Immutep to enact 20:1 ADS reverse split Sept. 28, 2026
Immutep Limited will change its ADS ratio from 1:10 to 1:200 (a 20:1 reverse split) effective Sept. 28, 2026, aiming to meet Nasdaq’s $1.00 minimum bid price after a deficiency notice.
EQUITY | Sep 21, 2026, 12:03 PM UTC
L
UK's ImmuPharma interim net loss widens on derivative finance loss
OverviewOutlookResult DriversCompany press release:Key DetailsReuters Recommended ReadsFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact re
EARNINGS | Sep 15, 2026, 06:17 AM UTC
L
RCS - Immupharma PLC - New peer-reviewed publication
RNS Number: 7136U Immupharma PLC 15 September 2026 15 September 2026ImmuPharma PLC("ImmuPharma" or the "Company")New peer-reviewed publication reports P140 activity in a preclinical MASH modelImmuPharma PLC LSE:IMM, the
NEWS | Sep 15, 2026, 06:02 AM UTC
L
IMM: Net loss increased to £4.7 million, but fundraising extends cash runway to H2 2028
Operating loss narrowed to £1.1 million, but net loss rose to £4.7 million due to a derivative asset revaluation. £6.47 million was raised to fund Kapiglucagon and P140, extending cash runway to H2 2028. Focus remains on
NEWS | Sep 15, 2026, 06:02 AM UTC
L
REG - Immupharma PLC - P140 International Patent Filing Update
RNS Number: 7135U Immupharma PLC 15 September 2026 This announcement contains inside information for the purposes of the UK Market Abuse Regulations ('UK MAR'). Upon publication of this announcement, this inside informat
NEWS | Sep 15, 2026, 06:01 AM UTC
L
REG - Immupharma PLC - Half-year Financial Report
RNS Number: 7134U Immupharma PLC 15 September 2026 RNS: RELEASE | 15th September 2026ImmuPharma PLC("ImmuPharma", the "Group" or the "Company")INTERIM RESULTSfor the six months ended 30 June 2026ImmuPharma PLC LSE:IMM, (
NEWS | Sep 15, 2026, 06:00 AM UTC
L
Immutep Target Price Cut 14% to A$0.07/Share by Bell Potter>IMM.AU
Immutep Target Price Cut 14% to A$0.07/Share by Bell Potter>IMM.AU
NEWS | Sep 15, 2026, 01:20 AM UTC
L
Immutep Gets a New Bull at Jefferies — Market Talk
Immutep gets a new bull at Jefferies, where analyst David Stanton sees a clearer potential development path for the biotechnology company's lead product candidate. Raising his recommendation to buy from hold, Stanton is
NEWS | Sep 15, 2026, 01:09 AM UTC
L
Immutep Raised to Buy From Hold by Jefferies >IMM.AU
Immutep Raised to Buy From Hold by Jefferies >IMM.AU
NEWS | Sep 15, 2026, 12:13 AM UTC
L
Immutep Target Price Raised to A$0.08/Share From A$0.04/Share by Jefferies>IMM.AU
Immutep Target Price Raised to A$0.08/Share From A$0.04/Share by Jefferies>IMM.AU
NEWS | Sep 15, 2026, 12:12 AM UTC
L
REG - Immupharma PLC - Holding(s) in Company
RNS Number: 2916U Immupharma PLC 10 September 2026 TR-1: Standard form for notification of major holdingsThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financia
EQUITY | Sep 10, 2026, 12:40 PM UTC
L
Immutep says no dividends paid or declared in current FY
Immutep said it has paid or declared no dividends during its current fiscal year.
EQUITY | Aug 31, 2026, 01:32 AM UTC
L
IMM says TACTI-004 discontinuation impaired results
IMM reports impairment linked to discontinued TACTI-004, citing strong cash and positive clinical data supporting future prospects.
EQUITY | Aug 30, 2026, 11:36 PM UTC